Comprehensive Overview of 6-Chloro-1H-indazole-3-carbaldehyde (CAS No. 885521-37-9): Properties, Applications, and Industry Insights
6-Chloro-1H-indazole-3-carbaldehyde (CAS No. 885521-37-9) is a high-value heterocyclic compound widely recognized for its versatile applications in pharmaceutical research and organic synthesis. This indazole derivative features a chloro-substituted aromatic ring and a reactive formyl group, making it a critical intermediate for designing bioactive molecules. Its molecular formula, C8H5ClN2O, and structural uniqueness have garnered significant attention from researchers exploring kinase inhibitors and anticancer agents.
In recent years, the demand for 6-Chloro-1H-indazole-3-carbaldehyde has surged due to its role in developing small-molecule therapeutics. A growing trend in AI-driven drug discovery has further highlighted its importance, as computational models frequently identify indazole scaffolds for targeted drug design. Searches for "indazole-based compounds in cancer research" or "CAS 885521-37-9 suppliers" reflect its commercial and scientific relevance. The compound’s crystallographic data and HPLC purity profiles are also frequently queried, underscoring the need for rigorous quality control in synthesis.
The synthesis of 6-Chloro-1H-indazole-3-carbaldehyde typically involves Vilsmeier-Haack formylation of 6-chloro-1H-indazole, a process optimized for high yield and minimal byproducts. Researchers emphasize its solubility in DMSO and stability under inert conditions, which are crucial for high-throughput screening applications. Notably, its electrophilic aldehyde group enables facile derivatization, supporting the creation of Schiff bases or hydrazone conjugates for medicinal chemistry projects.
From an industrial perspective, CAS 885521-37-9 aligns with the rising focus on green chemistry and sustainable synthesis. Manufacturers are increasingly adopting catalytic methods to reduce waste, responding to queries like "eco-friendly indazole synthesis." Additionally, its potential in photodynamic therapy and fluorescence probes has sparked interdisciplinary interest, linking it to trending topics such as "theranostic nanomaterials."
Regulatory compliance and patent landscapes surrounding 6-Chloro-1H-indazole-3-carbaldehyde are another focal point. With stringent REACH regulations in the EU and evolving FDA guidelines, suppliers must provide detailed COA documentation and stability studies. This aligns with frequent searches for "GMP-certified indazole derivatives" and "CAS 885521-37-9 safety data," reflecting user concerns about quality and traceability.
In conclusion, 6-Chloro-1H-indazole-3-carbaldehyde exemplifies the intersection of innovation and practicality in modern chemistry. Its adaptability in drug discovery pipelines, coupled with industry shifts toward sustainable practices, ensures its continued prominence. For researchers and procurement specialists, understanding its structure-activity relationships and scalable synthesis remains paramount to leveraging its full potential.
